• Molecular NameZanamivir
  • SynonymGANA; GNA; Modified sialic acid; Zanamavir; ZMR
  • Weight332.313
  • Drugbank_IDDB00558
  • ACS_NO139110-80-8
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)-3.31
  • pkaN/A
  • LogD (pH=7, predicted)-5.81
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-0.43
  • LogSw (predicted, AB/LogsW2.0)34.33
  • Sw (mg/ml) (predicted, ACD/Labs)123.97
  • No.of HBond Donors9
  • No.of HBond Acceptors11
  • No.of Rotatable Bonds7
  • TPSA198.22
  • StatusFDA approved
  • AdministrationInhalation
  • PharmacologyA neuraminidase inhibitor used in the treatment and prophylaxis of Influenzavirus A and Influenzavirus B.
  • Absorption_value2.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability2.0
  • Protein binding10.0
  • Volume of distribution (VD)16 L; decreases in patients with renal impairment (13.4 L in those with severe impairment; 15.1 L for mild–moderate impairment).
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmNot metabolized
  • Half life2.5~5.1 h
  • ExcretionRenal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A